Abstract
Malignant tumor is a major factor in global disease burden. In recent years, its incidence is still increasing year by year. Because of its complex etiology and the frequent recurrence and metastasis after general surgery, it brings great challenges to global public health. The emergence of new technology, that is, “Chimeric Antigen Receptor-T” immuno-therapy, has created a new era for the treatment of hematological malignant tumors, such as non-Hodgkin’s lymphoma and acute B-lymphocytic leukemia. In order to evaluate the killing effect of CART tumor immuno-therapy on tumor cells more intuitively, CD19-CART cells targeting B-cell lymphoma were constructed in vitro, combined with innovative in vitro real-time cellular analysis technology. Meanwhile, it is compared with common T lymphocytes in the human body to observe their killing activity against targeted tumors. The results showed that in comparison with common T lymphocytes, CD19-CART cells constructed in this paper showed significantly enhanced killing activity for targeting tumors and a dose-dependent effect on the ratio of response to the target. Besides, CD19-CART cells constructed in this paper have a remarkable killing effect on tumor cells and adopt superior technical methods to observe the killing activity more intuitively, which provides a solid theoretical basis for the clinical application of CART cell tumor immuno-therapy technology.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
